
|Videos|May 1, 2013
Patrick Gleason of Prime Therapeutics on Pharmacogenomic Testing
Patrick Gleason, PharmD, BCPS, FCCP, director of Health Outcomes at Prime Therapeutics, discusses the value of pharmacogenomic testing and the factors that influence whether a health plan or PBM will reimburse for the use of that test.
Advertisement
Patrick Gleason, PharmD, BCPS, FCCP, director of Health Outcomes at Prime Therapeutics, discusses the value of pharmacogenomic testing and the factors that influence whether a health plan or PBM will reimburse for the use of that test.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
CHEST 2025: Brensocatib Shows Potential to Slow Structural Lung Changes in Bronchiectasis
2
Pharmacists Can Drive Equitable Diagnostics Access, Improve Antimicrobial Resistance Stewardship
3
From Stigma to Breakthrough: Psychedelic Medicine
4
How Pharmacy and Public Health Partner to Combat Infectious Diseases
5